Using engineered blood vessels to treat heart defects in children
Readily Available Biological Conduits to Treat Single Ventricle Defects
This study is working on a new way to help kids with single ventricle heart defects by creating special blood vessels that can grow with them, using safe materials from human umbilical cords, to make their surgeries more successful.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10991036 on NIH RePORTER |
What this research studies
This research focuses on developing new biological conduits to treat single ventricle congenital heart defects in children. The approach involves creating tissue-engineered vascular conduits (TEVCs) that can grow and remodel as the child develops, using decellularized human umbilical arteries coated with endothelial cells derived from human induced pluripotent stem cells. By addressing issues of graft stenosis and immunocompatibility, this research aims to improve surgical outcomes for affected children. The study utilizes a validated animal model to test the effectiveness of these conduits before potential clinical application.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with single ventricle congenital heart defects.
Not a fit: Patients with other types of congenital heart defects or those over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the surgical treatment and long-term outcomes for children with single ventricle heart defects.
How similar studies have performed: Previous research has shown promise in using tissue-engineered vascular conduits, but this specific approach with hypoimmunogenic cells is novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Qyang, Yibing — Yale University
- Study coordinator: Qyang, Yibing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.